In this episode, Rich and Pip discuss a paper a German/Austrian study published in Blood: Kühne et al. Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.

The study is an observational, retrospective study reporting outcomes of patients with TTP who were treated without plasma exchange, which is currently considered the standard of care. The advent of a novel nanobody against vWF called caplacizumab, that targets and prevents catastrophic thrombosis that is seen in TTP, has allowed the study of this approach. Rich and Pip discuss the nuances of the paper and offer critical analysis.

In a follow-up episode, Rich and Pip will interview the study authors.

Hosted on Acast. See acast.com/privacy for more information.